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Poster Session I S277The patient was treated with a dose of 10 mg daily inhaled for 3 con-
secutive days. She tolerated the therapy well. Within one day of ini-
tiating treatment, the patient subjectively felt better. She did not
require supplemental oxygen by day 3 of therapy and was discharged.
Initial pulmonary function tests (PFTs) showed FEV1 of 0.76L and
DLCO was 36% of predicted. Subsequent PFTs showed FEV1 of
0.91L and DLCO was 53% of predicted. Serial samples from nasal
and oral sites were taken and showed reduction of PIV virus loads
as measured by PCR.
Table 1. Parainfluenza viral load as measured by PCR from
oral and nasal sites
Day Site PIV3 copies / ml1 Oral 1.47 E4
3 Oral 2.90 E3
1 Nasal 1.72 E7
3 Nasal 7.30 E4In vitro testing of the infecting PIV strain showed an inhibitory
dose between 10-100 nM. One week later, the patient’s respiratory
symptoms worsened. She was found to have evidence of persistent
PIV3 infection as well as relapse of AML. Treatment was initiated
with a second course of DAS181, but her AML progressed rapidly
and she died from complications of AML. The cause of death was
unrelated to PIV infection. Treatment with inhaled DAS181 clearly
brought about a clinical improvement as evidenced by improved
symptoms, PFTs, exam, and decrease in PIV virus load. Longer
treatment may be required in SCT recipients. DAS181 administra-
tion for treatment of PIV infections should be systematically tested
in patient groups at risk for severe disease.339
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Introduction: Autologous hematopoietic stem cell transplant (auto-
HCT) recipients have a high incidence of herpes zoster (HZ) follow-
ing transplant. The primary objective of this study was to estimate
the incremental medical resource utilization (RU) and costs associ-
ated with HZ in the auto-HCT population from HZ diagnosis
through 3 months after diagnosis with HZ.
Methods:Claims data (1999-2007) was assessed to determine the in-
cremental medical RU and cost due to HZ from Thomson Reuters
MarketScan Research Databases (Commercial and Medicare).
Cases were selected if they had an ICD-9-CM diagnostic code for
HZ following an ICD-9-CM procedure code for auto-HCT and
matched 1:1 via propensity scores to auto-HCT controls without
HZ. Differences in selected treatment and clinical characteristics
were assessed using t-tests for continuous variables and chi-square
tests for categorical variables. The analysis of resource use and costs
was limited to claims that could potentially be related to the treat-
ment of HZ. A two-part model (logistic regression / negative bino-
mial generalized linear model) was selected for multivariate
analysis of incremental medical RU and costs.
Results: One-hundred-twenty-four HZ cases were included in the
analysis (92% of these occurred within 2 years of the auto-HCTpro-
cedure). Over the 3 month analysis period, there were 20 hospitali-
zations with HZ as the principle diagnosis (0 for controls), 17
cases of ophthalmic HZ (0 for controls) and 21 cases with neurolog-
ical impairment due toHZ (0 for controls). There were no claims for
disseminated HZ or for the administration of IV acyclovir within 7
days of HZ diagnosis. Auto-HCT recipients with HZ had signifi-
cantly more medical service utilization in all categories (inpatient
admissions, average length of stay, emergency room visits, number
of outpatient visits, number of other outpatient services, and out
patient prescriptions) compared to controls (p\ 0.01). HCT pa-
tients with HZ had significant incremental medical costs due to
HZ (See Table 1).Table 1. Potentially HZ Related Medical Costs for auto-HCT
Recipients
N O bserved AdjustedAuto-HCTwith HZ 124 $8,229 $8,222
Auto-HCTwithout HZ 124 $1,526 $1,371Incremental Cost (95% CI) $6,703 $6,852 ($2,554 - $11,553)Conclusions: Herpes zoster has a significant impact on the health,
medical service use and medical costs for auto-HCT recipients. Fu-
ture advances for the treatment or prevention of HZ in auto-HCT
recipients should be given strong consideration to help alleviate
this medical burden.340
COLLAPSED-DOSE VERSUS STANDARD-DOSE PALIFERMIN THERAPY IN
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kim, S.S.1, Ng, A.1, Caliendo, G.1, Meyer, J.1, Isola, L.2 1The Mount
SinaiMedical Center, New York, NY; 2TheMount Sinai Medical Center,
New York, NY
Oral mucositis (OM) is a complication frequently associated with
hematopoietic stem cell transplantation (HSCT) following high-
dose chemotherapy with or without total body irradiation (TBI).
Severe OM increases the requirement for both IV opioids and total
parenteral nutritions (TPN), risk of infection, and subsequently pro-
longs the length of hospital stay (LOS). Palifermin, a keratinocyte
growth factor, is the only agent approved for the prevention of severe
OM in patients undergoing HSCT for hematologic malignancies.
The FDA-approved dosing of palifermin is 60 mcg/kg/day for 3
days pre-HSCT, followed by 60 mcg/kg/day for 3 days post-
HSCT. In limited data, collapsed-dose palifermin regimens offered
similar efficacy and safety profiles while providing more convenient
dosing schedules compared to the standard-dose regimen. Of the
two published collapsed-dose regimens, The Mount Sinai Medical
Center has adapted the following dosing schedule: 180 mcg/kg as
a single-dose pre-HSCT, followed by 60 mcg/kg/day for 3 consecu-
tive days post-HSCT. To compare the safety and efficacy between
the collapsed-dose and standard-dose palifermin, a 2-year retrospec-
tive study (June 2007 toMay 2009) was performed at our institution.
The primary objective was to assess the overall safety and efficacy of
collapsed-dose palifermin. The secondary objectives included asses-
ssment of the safety and efficacy of collapsed-dose palifemin with re-
duced intensity chemotherapy (RIC). Of the 81 patients treated with
palifermin, 43 received standard-dose, while 38 received collapsed-
dose. In the RIC group (n 5 35), 19 received standard-dose and 16
received collapsed-dose. Overall, there were no significant differ-
ences in the incidence of severe OM, requirements for TPN and
IV opioid usage, and the LOS between the two dosing groups; safety
profiles between the two dosing schedules have also been shown to
be comparable. Furthermore, a subgroup analysis in the RIC group
showed no significant differences in the incidence of severe OM, IV
opioid requirement, and LOS between the two dosing arms, with the
exception of the TPN requirement for which collapsed-dose arm
was associated with a higher rate of requirement than the stan-
dard-dose arm (63% vs. 26%, p5 0.04); the safety profile of palifer-
min between the two dosing groups have also been shown to be
similar. Our data supports the use of collapsed-dose palifermin as
a reasonable alternative to standard-dose palifermin regimen.341
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Background: Infections are a leading complication following cord
blood transplantation (CBT), but data on the rate of invasive fungal
infections (IFI) in this population are limited.
